Free tool
FAERS Monitor: Lialda
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022000 or its brand name (Lialda, Mesalamine). Reports on generic versions are filed under their own applications.
Reports
36,767
Serious
29,039
79% of reports
Hospitalization
11,298
Death reported
2,144
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use6,841
- drug ineffective5,388
- colitis ulcerative5,375
- condition aggravated3,686
- diarrhoea3,406
- haematochezia2,959
- fatigue2,745
- abdominal pain2,577
- headache2,274
- nausea2,274
- pyrexia2,151
- weight decreased2,149
- frequent bowel movements2,006
- pain1,985
- arthralgia1,982
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 106 |
| 2005 | 149 |
| 2006 | 106 |
| 2007 | 165 |
| 2008 | 638 |
| 2009 | 274 |
| 2010 | 367 |
| 2011 | 951 |
| 2012 | 959 |
| 2013 | 638 |
| 2014 | 1,219 |
| 2015 | 1,654 |
| 2016 | 1,455 |
| 2017 | 1,062 |
| 2018 | 1,202 |
| 2019 | 1,226 |
| 2020 | 1,578 |
| 2021 | 2,800 |
| 2022 | 4,468 |
| 2023 | 4,564 |
| 2024 | 4,371 |
| 2025 | 4,286 |
| 2026 | 2,528 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,017,392 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| colitis ulcerativeSignal | 5,375 | 78.0 | 76.0 | 360,407 |
| frequent bowel movementsSignal | 2,006 | 45.8 | 43.8 | 81,456 |
| haematocheziaSignal | 2,959 | 32.3 | 31.2 | 85,261 |
| condition aggravatedSignal | 3,686 | 7.0 | 6.8 | 19,025 |
| abdominal painSignal | 2,577 | 6.4 | 6.2 | 11,728 |
| off label useSignal | 6,841 | 4.5 | 4.4 | 19,253 |
| weight decreasedSignal | 2,149 | 4.4 | 4.3 | 5,736 |
| pyrexiaSignal | 2,151 | 3.6 | 3.4 | 4,023 |
| diarrhoeaSignal | 3,406 | 3.0 | 2.9 | 4,749 |
| arthralgiaSignal | 1,982 | 2.7 | 2.6 | 2,213 |
| drug ineffectiveSignal | 5,388 | 2.3 | 2.3 | 4,411 |
| headacheSignal | 2,274 | 2.1 | 2.0 | 1,306 |
| fatigueSignal | 2,745 | 2.0 | 1.9 | 1,463 |
| pain | 1,985 | 1.9 | 1.8 | 797 |
| nausea | 2,274 | 1.6 | 1.6 | 596 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.